Haider S Mahdi
UPMC Magee Women's Hospital, UPMC Hillman Cancer Center · NRG Oncology · University of Pittsburgh Cancer Institute LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Haider S Mahdi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:13 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06161493 · ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsHaider Mahdi · withdrawn · Ovarian Cancer, Recurrent Solid Tumors · principal investigator
- Ph2NCT06126276 · Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)National Cancer Institute (NCI) · recruiting · Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm · principal investigator
- Ph1NCT05807126 · Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsNational Cancer Institute (NCI) · withdrawn · Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
- Ph2NCT05145569 · Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian CancerHaider Mahdi · withdrawn · Ovarian Cancer · principal investigator
- Ph2NCT05112601 · Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaNational Cancer Institute (NCI) · recruiting · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma · principal investigator
- Ph1NCT04840589 · Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsNational Cancer Institute (NCI) · suspended · Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 2: Combination PARPi-BETi to Overcome PARPi ResistanceP50CA272218 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2023 to 2025 · $696,589 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT06126276, NCT05112601
- NCI ETCTN Pittsburgh Cancer Consortium (PCC)UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2014 to 2026Named on NCT05807126, NCT04840589
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.